Clinical trials: ALS (Amyotrophic Lateral Sclerosis)
ALS
National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA Bank
This study will identify living veterans with amyotrophic lateral sclerosis (ALS) through a national registry that is being developed. Diagnosis of ALS will be verified by study neurologists via medical record review.
- Trial name
- ALS Registry (NCT00076154)
- Where
- United States
- Volunteers
- 2,121 people
- Sponsor
- US Department of Veterans Affairs
Amyotrophic Lateral Sclerosis
Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)
The purpose of the study is to evaluate the safety of sodium phenylbutyrate (NaPB) treatment in subjects with amyotrophic lateral sclerosis (ALS) and the ability to take this medication without major side effects.
- Trial name
- NCT00107770
- Testing
- sodium phenylbutyrate
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- US Department of Veterans Affairs
Amyotrophic Lateral Sclerosis
Exercise and Disease Progression in Amyotrophic Lateral Sclerosis Patients
This study evaluated the influence of a tailored aerobic exercise protocol on the functional outcome in ALS patients. In addition, the investigators compare some CPET variables collected during exercise testing in both groups.
- Trial name
- NCT03326622
- Testing
- standard care, moderate exercise
- Volunteers
- 48 people
- Sponsor
- University of Lisbon
ALS (Amyotrophic Lateral Sclerosis)
Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited.
- Trial name
- UNZUELUZON ALS (NCT07737977)
- Testing
- peripheral venous blood collection, collection of medical data related to patient care
- Where
- 2 sites in France, Spain
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
ALS
NF-κB Inhibition in Amyotrophic Lateral Sclerosis
This is a Phase II, single centre, randomized, parallel, double blind, placebo-controlled clinical trial to determine the safety of Withania somnifera in participants with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NIALS (NCT05031351)
- Testing
- Withania somnifera
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- Sunnybrook Health Sciences Centre
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), Alzheimer Disease
- Trial name
- MESO7 (NCT07202494)
- Testing
- Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging)
- Where
- France
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Amyotrophic Lateral Sclerosis, Respiratory Function
The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS
Thirty cases of amyotrophic lateral sclerosis patients were recruited from the neurology department of Ruijin Hospital, the pain department and the encephalopathy center of Luwan Branch of Ruijin Hospital.
- Conditions
- Amyotrophic Lateral Sclerosis, Respiratory Function, Scopolamine
- Trial name
- NCT04391361
- Testing
- Scopolamine, atropine, edaravone and dexmedetomidine, Edaravone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Amyotrophic Lateral Sclerosis (ALS)
Examining Interactions Between PALS and Caregivers
The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and their caregivers.
- Trial name
- NCT06819124
- Testing
- Structured Communicative Interaction, Unstructured communicative interaction
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Penn State University
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease
This is a randomised, double-blind, placebo controlled study on a cannabis-based medicine extract (MediCabilis CBD Oil), in patients with Amyotrophic Lateral Sclerosis or Motor Neurone Disease.
- Trial name
- NCT03690791
- Testing
- MediCabilis CBD Oil
- Where
- Australia
- Volunteers
- 17 people
- Sponsor
- Gold Coast Hospital and Health Service
Amyotrophic Lateral Sclerosis
Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)
Dysphagia (swallow impairment), dystussia (cough impairment) and respiratory impairment are hallmark features of amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT02710110
- Testing
- PowerLung trainer, Micro Mouth Pressure Meter, Pulmonary Function Testing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Amyotrophic Lateral Sclerosis
A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This study will examine whether fasudil is effective and safe in treating patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT01935518
- Testing
- Fasudil
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University Third Hospital
Amyotrophic Lateral Sclerosis
Ultra-high-caloric, Fatty Diet in ALS
This study aims at evaluating efficacy and tolerability of an ultra-high-caloric, fatty diet (UFD) compared to placebo in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- LIPCAL-ALS II (NCT06280079)
- Testing
- Ultra-high-caloric fatty diet
- Where
- 23 sites in Germany
- Volunteers
- 399 people
- Sponsor
- University of Ulm
Amyotrophic Lateral Sclerosis
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- DAZALS (NCT05407324)
- Testing
- Dazucorilant 300 mg, Dazucorilant 150 mg, Dazucorilant
- Where
- 35 sites in United States, Belgium and 8 more
- Volunteers
- 279 people
- Sponsor
- Corcept Therapeutics
Locked in Syndrome, ALS (Amyotrophic Lateral Sclerosis)
Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS)
Eighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment.
- Trial name
- SpeechBCI (NCT07698496)
- Testing
- Chronic speech BCI
- Where
- 4 sites in France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Grenoble
Amyotrophic Lateral Sclerosis ALS
Intestinal Microbiome Transplant in ALS
This is a 24-week study of intestinal microbiome transplant in people with ALS. All participants will be evaluated clinically in person for 4 visits. Blood and mailed/ fresh stool samples will also be collected.
- Trial name
- NCT07017946
- Testing
- MTP-101C
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Parkinson Disease, Amyotrophic Lateral Sclerosis
Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's…
- Trial name
- PROBE (NCT05542576)
- Testing
- AMDX2011P
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Amydis Inc.
ALS
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale- Revised (ALSFRS-R) score from baseline up to…
- Trial name
- NCT04569084
- Testing
- MT-1186
- Where
- 95 sites in United States, Canada and 5 more
- Volunteers
- 384 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis
Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis
The drug for this submission is Hope Biosciences' autologous, adipose-derived culture-expanded mesenchymal stem cells (HB-adMSCs) for the treatment of a single patient with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT04514952
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Amyotrophic Lateral Sclerosis
Open Label Extension of TUDCA-ALS Study
This study will provide extended access to patients and assess longer-term outcomes on patients who have completed the TUDCA-ALS study.
- Trial name
- TUDCA-ALS OLE (NCT05753852)
- Testing
- Tauroursodeoxycholic Acid
- Where
- 23 sites in Belgium, France and 5 more
- Volunteers
- 184 people
- Sponsor
- Humanitas Mirasole SpA
Amyotrophic Lateral Sclerosis
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)
- Trial name
- REAL (NCT05218668)
- Testing
- Fasudil (WP-0512)
- Where
- 12 sites in United States, Australia
- Volunteers
- 40 people
- Sponsor
- Woolsey Pharmaceuticals